Literature DB >> 23702386

The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.

Geeta Hampson1, Sylvie Edwards, Soraya Conroy, Glen M Blake, Ignac Fogelman, Michelle L Frost.   

Abstract

Epidemiological studies have shown an association between bone loss/osteoporosis and vascular calcification (VC). Recent studies have implicated the Wnt signalling pathway in the pathogenesis of VC. We investigated the association between circulating concentrations of Wnt inhibitors; DKK1 and sclerostin with bone mineral density (BMD), abdominal aortic calcification (AAC) and arterial stiffness in post-menopausal women. One hundred and forty six post-menopausal women aged (mean [SD]) 61.5[6.5] years were studied. Sclerostin and DKK1 were measured in serum. BMD was measured at the lumbar spine (LS), femoral neck (FN), total hip (TH). AAC was detected by Vertebral Fracture Assessment (VFA) imaging and quantified using an 8- and 24- point scoring methods. Arterial stiffness was determined by aortic pulse wave velocity (PWV). A significant positive correlation was observed between sclerostin and BMD at the FN (r = 0.166, p = 0.043) and TH (r = 0.165, p = 0.044). The association remained significant at the FN (p = 0.045) and TH (p = 0.026) following adjustment for confounders. No significant correlation was observed between DKK1 and BMD. In contrast, there was a significant negative correlation between log DKK1 and AAC (24-point score: r = -0.25, p = 0.008 and 8-point score: r = -0.21, p = 0.024). Subjects with AAC score of 1 or less had significantly higher DKK1 (p = 0.01). The association between DKK1 and AAC remained significant following correction for age, blood pressure, cholesterol (24-point score: p = 0.017, 8-point score: p = 0.044). In adjusted linear regression analysis, sclerostin was positively associated with AAC (24-point score: p = 0.048, 8-point score: p = 0.031). Subjects with a PWV>9 m/s had significantly higher sclerostin than those with PWV <9 m/s: 23.8[12.3], vs 29.7 [14] pmol/l, p = 0.03). No association was observed between DKK1 and PWV. The opposite association between AAC and the 2 Wnt signaling inhibitors is of interest and merits further investigations. Future longitudinal studies are needed to establish the precise role of sclerostin and DKK1 in the pathogenesis of VC.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Keywords:  Bone mineral density; DKK1; Sclerostin; Vascular calcification

Mesh:

Substances:

Year:  2013        PMID: 23702386     DOI: 10.1016/j.bone.2013.05.010

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  47 in total

Review 1.  Sclerostin: a new biomarker of CKD-MBD.

Authors:  Andreja Figurek; Merita Rroji; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

2.  Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study.

Authors:  Thomas C Register; Keith A Hruska; Jasmin Divers; Donald W Bowden; Nicholette D Palmer; J Jeffrey Carr; Lynne E Wagenknecht; R Caresse Hightower; Jianzhao Xu; S Carrie Smith; Dennis J Dietzen; Carl D Langefeld; Barry I Freedman
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

Review 3.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

Review 4.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 5.  The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.

Authors:  Núria Guañabens; Laia Gifre; Pilar Peris
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

6.  Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.

Authors:  P Wanby; R Nobin; S-P Von; L Brudin; M Carlsson
Journal:  J Endocrinol Invest       Date:  2016-02-05       Impact factor: 4.256

Review 7.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

8.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

9.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

Review 10.  Bone kidney interactions.

Authors:  Thomas L Nickolas; Sophie A Jamal
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.